Please find below a link to MSF’s report-- released at the Union 2018 conference-- with latest pricing and an an analysis of access barriers for drug-resistant TB drugs
DR-TB DRUGS UNDER THE MICROSCOPE
Despite some positive updates, access to safe & effective treatment remains poor
The report covers topics:
WHO issued new recommendations (August 2018) for improved DR-TB treatment include using all-oral regimens, making bedaquiline one of three core drugs to be used in all MDR-TB treatment regimens, and dropping the use of second-line injectable medicines.
These changes more than doubles the number of people for whom bedaquiline-containing regimens are recommended
Although bedaquiline and delamanid can significantly improve treatment outcomes and reduce side effects, they remained inaccessible to nearly 90% of people eligible to receive them in 2017.
Finally, a bit of good news for children with DR-TB: 6 critical paediatric formulations are quality assured through WHO Pre-Qualification or other mechanisms
The report also includes prices of regimens and individual key drugs, such as bdeaquiline, delamanid, clofazamine and linezolid.
Prices have decreased for some key DR-TB drugs. Over the past six years, GDF prices for conventional DR-TB regimens (those recommended by WHO until the latest August 2018 announcement) significantly dropped – by up to 200% for some regimens
However, high prices include J&J’s price of six months of bedaquiline which US$400 (US$67/month) for all countries procuring through GDF.
The estimated price of longer individualized treatment regimens could now reach more than US$2,000 for people who need at least 18 months of bedaquiline, which would represent a 50% price increase over previous standard treatment.
Otsuka keeps its GDF price high at US$1,700 of a six-month treatment (US$283 per month)
The price for people needing both bedaquiline and delamanid for as long as 20 months, the price increase could reach 500%, with a treatment regimen priced at around $9,000.
The report’s supplement includes more information on pricing, registration, sources, dosing, and paeds formulations. It can be found here: https://msfaccess.org/sites/default/files/2018-10/TB_Supplement_UTM_ENG_2018.pdf
Threats to DR-TB treatment scale-up
The Global Fund ‘procurement cliff’: We provide an analysis of the shift from internationally-supported procurement (with multiple suppliers and competitive volume-driven prices) to national purchase of TB drugs and diagnostics and related risks to QUALITY, AFFORDABILITY, and SUPPLY
Lack of national registration of key DR-TB drugs remains a problem, which will be acerbated to the switch to national procurement, given that many countries provide a blanket waiver to commodities procured with Global Fund support.
Should you have questions for our subject-matter experts, including Christophe Perrin the drug-related issues, please write to .